PURPOSE: Descriptions of late morbidity after radiotherapy in cervical cancer survivors (CCSs) are usually based on observations made by physicians, and rarely by patients themselves. We describe and compare physician-assessed morbidity with patient-rated symptoms more than 5 years after pelvic radiotherapy. METHODS AND MATERIALS: In 147 CCSs treated between 1994 and 1999 at The Norwegian Radiumhospital, morbidity data were regularly documented by physicians at least for 5 years after radiotherapy. Information on patient-rated symptoms was collected by a questionnaire from 91 (62%) of the 147 survivors after a median follow-up time of 96 months (65-131 months). The results were compared with physician-assessed morbidity scores recorded at 5 years, and to selected normative data using descriptive statistics. Physician-assessed morbidity data were modeled using Kaplan-Meier method. Agreement between physician data and patient data was expressed using weighted kappa statistics. RESULTS: The 5-year Kaplan-Meier estimates of physician-assessed intestinal, bladder, and vaginal morbidity Grade 3-4 were 15%, 13%, and 23%, respectively. The prevalence of patient-rated severe symptoms from these organs was much higher (intestines 45%, bladder 23%, and 58% vaginal discomfort among sexually active CCSs). Poor agreement was confirmed by low values of kappa: For bladder the concordance was slight (kappa = 0.16) and for intestine it was fair (kappa = 0.27). Stress incontinence, diarrhea, nausea, and sexual problems were significantly (p < 0.001) more prevalent when compared with a control sample from the general female population. CONCLUSIONS: Morbidity is common after pelvic radiotherapy. However, our data indicate that physicians underreport patients symptoms. It is important to incorporate patient-reported outcomes in the evaluation of treatment-related morbidity.
PURPOSE: Descriptions of late morbidity after radiotherapy in cervical cancer survivors (CCSs) are usually based on observations made by physicians, and rarely by patients themselves. We describe and compare physician-assessed morbidity with patient-rated symptoms more than 5 years after pelvic radiotherapy. METHODS AND MATERIALS: In 147 CCSs treated between 1994 and 1999 at The Norwegian Radiumhospital, morbidity data were regularly documented by physicians at least for 5 years after radiotherapy. Information on patient-rated symptoms was collected by a questionnaire from 91 (62%) of the 147 survivors after a median follow-up time of 96 months (65-131 months). The results were compared with physician-assessed morbidity scores recorded at 5 years, and to selected normative data using descriptive statistics. Physician-assessed morbidity data were modeled using Kaplan-Meier method. Agreement between physician data and patient data was expressed using weighted kappa statistics. RESULTS: The 5-year Kaplan-Meier estimates of physician-assessed intestinal, bladder, and vaginal morbidity Grade 3-4 were 15%, 13%, and 23%, respectively. The prevalence of patient-rated severe symptoms from these organs was much higher (intestines 45%, bladder 23%, and 58% vaginal discomfort among sexually active CCSs). Poor agreement was confirmed by low values of kappa: For bladder the concordance was slight (kappa = 0.16) and for intestine it was fair (kappa = 0.27). Stress incontinence, diarrhea, nausea, and sexual problems were significantly (p < 0.001) more prevalent when compared with a control sample from the general female population. CONCLUSIONS: Morbidity is common after pelvic radiotherapy. However, our data indicate that physicians underreport patients symptoms. It is important to incorporate patient-reported outcomes in the evaluation of treatment-related morbidity.
Authors: Stefan Stefanovic; Markus Wallwiener; Uros Karic; Christoph Domschke; Luka Katic; Florin-Andrei Taran; Aleksandra Pesic; Andreas Hartkopf; Peyman Hadji; Martin Teufel; Florian Schuetz; Christof Sohn; Peter Fasching; Andreas Schneeweiss; Sara Brucker Journal: Support Care Cancer Date: 2016-10-17 Impact factor: 3.603
Authors: Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Aparna S Ramaseshan; Jessica Felton; Dana Roque; Gautam Rao; Andrea G Shipper; Tatiana V D Sanses Journal: Int Urogynecol J Date: 2017-09-19 Impact factor: 2.894
Authors: K Kirchheiner; R Nout; J Lindegaard; P Petrič; E V Limbergen; I-M Jürgenliemk-Schulz; C Haie-Meder; R Pötter; W Dörr Journal: Strahlenther Onkol Date: 2012-08-17 Impact factor: 3.621
Authors: Avani D Rao; Elizabeth A Sugar; Daniel T Chang; Karyn A Goodman; Amy Hacker-Prietz; Lauren M Rosati; Laurie Columbo; Eileen O'Reilly; George A Fisher; Lei Zheng; Jonathan S Pai; Mary E Griffith; Daniel A Laheru; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Albert Koong; Joseph M Herman Journal: Pract Radiat Oncol Date: 2016-05-25
Authors: Heidi J Gray; Erin Seifert; Victor G Sal Y Rosas; Katrina F Nicandri; Wui-Jin Koh; Barbara A Goff Journal: Obstet Gynecol Int Date: 2010-04-28
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Donald S Kaufman; Michael P Hagan; Niall M Heney; Howard M Sandler Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544